Long Term Safety and Efficacy Study of Tanezumab in Japanese Adult Subjects With Chronic Low Back Pain
Status:
Completed
Trial end date:
2019-06-11
Target enrollment:
Participant gender:
Summary
This study will investigate the long-term safety and efficacy of a fixed dose of tanezumab 5
mg and 10 mg administered subcutaneously (SC) seven times at 8 week intervals. The primary
objective of this study is to evaluate the long term safety of tanezumab 5 mg and 10 mg
administrated SC every 8 weeks (7 administrations). In addition, the study will evaluate the
long term analgesic efficacy of tanezumab 5 mg and 10 mg SC administered every 8 weeks (7
administrations).